Investor Overview

Corporate Summary

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. We are developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Our technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication.

  • Signed a merger agreement with Cend Therapeutics, creating Lisata Therapeutics, which will be a public company with a diverse pipeline of clinical stage product candidates in multiple indications
  • CD34+ cell therapy platform yielding a multi-product development pipeline with 2 clinical programs having regenerative medicine “breakthrough” designation
  • Proprietary field-leading technology in lucrative global indications backed by a strong IP portfolio
  • Potential value creating events in the next 12-24 months based on milestones across the pipeline
  • Strong balance sheet [$88.5 million cash & investments (as of 3/31) - no debt]; well-positioned relative to projected capital needs for current development programs and cash balance target at merger closing
  • Seasoned management with noteworthy domain expertise along with big pharma and emerging biotech experience